AstraZeneca stock sinks as management announces $2 billion investment in Summit Therapeutics. But should you buy the dip in ...

AstraZeneca just locked in a price to own 12% of Summit Therapeutics that the open market refuses to match, and two clinical ...

At the close on September 9, 2026, AstraZeneca stock fell 2.0 percent to USD 156.89 on the NYSE, while the broader S&P 500 slipped 0.6 percent. Today, investors watch AstraZeneca stock amid fresh US ...

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

AstraZeneca's medicine Wainua did not meet its goal of reducing deaths and recurrent heart-related emergencies in people with a rare heart condition. Shares slumped and were on track for the worst day ...

AstraZeneca stock edged lower despite the US FDA granting accelerated approval for the company’s new breast cancer pill ...

AstraZeneca will put about $2 billion into Summit after the latter flagged in July that its cash pile was not enough to fund planned operations for a full year.

I'm initiating coverage on AstraZeneca (AZN) and setting it at a "Strong Buy" rating. The reason why is because the company was able to report massive growth in revenue in Q1 of 2026. During this ...

AstraZeneca gets a Buy rating as its core business is still growing while a deep late-stage pipeline gives investors multiple ways for earnings. Click for more.